The U.S. Food and Drug Administration approved Biogen’s aducanumab, the first drug to target an underlying cause of Alzheimer’s disease. The drug, to be sold under the brand Aduhelm, is the first new approval of an Alzheimer’s drug since 2003 and the only treatment designed to slow progression of the mind-robbing disease.
U.S. lawmakers from both parties and both houses of Congress introduced eight antitrust bills aimed at tackling the problem of high and rising drug prices, including bills to stop brand name drug companies from paying generic firms to stay off the market.
Jean-Noel David, Managing Director at Seqens CDMO NA, identifies six key trends that promise to reshape the pharma landscape during 2021 and beyond.
Catalyst Pharmaceuticals filed new patent infringement lawsuits against Jacobus Pharmaceuticals and PANTHERx Rare LLC over a treatment for the rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS).
U.S. President Donald Trump signed four executive orders designed to reduce drug costs for consumers, in a bid to highlight his commitment to cutting prescription prices ahead of the November presidential election.
The Federal Trade Commission filed a complaint in federal court against Vyera Pharmaceuticals, the company formerly known as Turing Pharmaceuticals that Martin Shkreli founded, alleging an “elaborate anticompetitive scheme to preserve a monopoly” on Daraprim.
Changes in U.S. Food and Drug Administration procedures meant to speed approvals for medications may have resulted in less exacting standards, a new analysis suggests.
Eli Lilly and Co. plans to sell two versions of insulin products at half their current U.S. list prices, eight months after the drug manufacturer started selling a half-priced version of the widely used Humalog injection.
Novo Nordisk will offer free, one-time supply of insulin to people in immediate need and at risk of rationing the medication.
Novartis won FDA approval for a long-delayed version of Amgen’s $4 billion seller Neulasta drug, helping the Swiss drugmaker in an uphill battle to sell copies of rivals’ blockbusters in the U.S.